WHO | Definitions
Adverse reaction WHO, (1972) • 'A response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modifications of physiological function'.
Download WHO | Definitions
Information
Domain:
Source:
Link to this page:
Documents from same domain
INVESTING IN HEALTH FOR ECONOMIC …
www.who.int2 INVESTING IN HEALTH FOR ECONOMIC DEVELOPMENT Report by the Mexican Commission on Macroeconomics and health 3 The …
WHO GOOD PRACTICES FOR PHARMACEUTICAL …
www.who.intworking document qas/09.297/rev.2 page 2 schedule for the proposed adoption process of document qas/09.297/rev.2: who good practices for pharmaceutical microbiology laboratories
NORMES ET STANDARDS EN INFRASTRUCTURES …
www.who.intnormes et standards en infrastructures et equipements du centre de sante et de promotion sociale, du centre medical avec antenne chirurgicale et du …
Heterotrophic Plate Count Measurement in …
www.who.intWorld Health Organization Sustainable Development and Healthy Environments Heterotrophic Plate Count Measurement in Drinking Water Safety Management
Annex 3 WHO good manufacturing practices for ...
www.who.int96 Introduction The fi rst WHO draft text on good manufacturing practices (GMP) was prepared in 1967 by a group of consultants at the request of the Twentieth
Annex 5 WHO good distribution practices for …
www.who.int236 1. Introduction Distribution is an important activity in the integrated supply-chain management of pharmaceutical products. Various people and entities are
Annex 2 WHO good practices for pharmaceutical …
www.who.int71 Introduction and scope of document Pharmaceutical microbiology laboratories may be involved in: — sterility testing; — detection, isolation, enumeration and identifi cation of microorganisms
LABORATORY BIOSAFETY MANUAL - WHO
www.who.intinterim guidelines WHO/CDS/CSR/LYO/2003.4 LABORATORY BIOSAFETY MANUAL SECOND EDITION (REVISED) WORLD HEALTH ORGANIZATION Geneva 2003
Mycobacteriology Laboratory Manual - WHO
www.who.intMycobacteriology Laboratory Manual ii Edita Pimkina, Infectious Diseases and Tuberculosis Hospital Affi liate of Public institution …
Laboratory Guidelines for enumerating CD4 T …
www.who.intSEA-HLM-392 Distribution: Limited Laboratory Guidelines for enumerating CD4 T Lymphocytes in the context of HIV/AIDS Regional Office for South-East Asia
Related documents
Pharmacovigilance and Risk Management - Elsevier
www.elsevier.comthe assessment of benefit versus risk must begin during the preclinical evaluation of a medic- ... (causality) to the investigational product, and reported to the regulatory authorities and other stakeholders, either as an expedited report or as part of an aggregate report, based upon ... Adverse drug reaction
The Basics on Adverse Event Monitoring, Assessment and ...
www.bumc.bu.eduthere is a reasonable possibility that the drug caused the adverse event….. _ – ZReasonable possibility: evidence to suggest a causal relationship between the drug and the adverse event. (21 CFR 312.32) •Adverse reaction: Subset of suspected adverse reactions – ^Any adverse event caused by a drug. (FDA Guidance, 12/12) 17 Adverse event
COVID-19 vaccine safety update
www.cdc.govVaccine Adverse Event Reporting System (VAERS) Strengths. National data Rapidly detects safety signals Can detect rare adverse events Data available to public. Limitations. Reporting bias Inconsistent data quality and completeness of information Lack of unvaccinated comparison group Not designed to assess causality ‒ ‒
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euIn accordance with the ICH-E2A guideline, the definition of an adverse reaction implies at least a reasonable possibility of a causal relationship between a suspected medicinal product and an adverse event. An adverse reaction, in contrast to an adverse event, is …
5.3.6 CUMULATIVE ANALYSIS OF POST …
drtrozzi.orgreported from clinical studies regardless of causality assessment. The limitations of post-marketing adverse drug event reporting should be considered when interpreting these data: • Reports are submitted voluntarily, and the magnitude of underreporting is unknown.
Revised AEFI Guidelines: Executive Summary
main.mohfw.gov.inCausality Assessment is the systematic evaluation of the information obtained about an AEFI to determine the likelihood of the event having been caused by the vaccine/s received. It is a critical part of AEFI monitoring and enhances confidence in the national immunization programme. The revised guidelines use the new revised WHO/CIOMS Causality ...